Seikagaku Corporation

Eiji Nanba

Yoshiyuki Suzuki

Seiichiro Ogawa

Junichiro Matsuda

Kousaku Ohno

Methods for stabilizing &#x3b2;-galactosidase, stabilizing &#x3b2;-glucocerebrosidase, treating a glycolipid metabolic disorder caused by mutation of &#x3b2;-galactosidase gene, treating a glycolipid metabolic disorder caused by mutation of &#x3b2;-glucocerebrosidase gene, regenerating the activity of &#x3b2;-galactosidase, regenerating the activity of &#x3b2;-glucosidase, treating GM1 gangliosidosis, Morquio-B or Krabbe's disease, and treating Gaucher's disease, include administering a carba-sugar amine derivative represented by the following formula (1) or (2): 

Carba-sugar amine derivative and glycolipid metabolic disorder treating agent containing the same as active ingredient

A carba-sugar amine derivative represented by the following formula (1) or (2) is used as the active ingredient of a &#x3b2;-galactosidase inhibitor or a glycolipid metabolic disorder treating agent.  Wherein each of Rand Rindependently represents H, an alkyl group, an acyl group, an aryl group or an aralkyl group, with the proviso that both are not H at the same time, and each of R, R, Rand Rindependently represents a hydroxyl group or hydroxyl group having a substituent. Also, Rrepresents an alkyl group, and each of R, R, Rand Rindependently represents a hydroxyl group or a hydroxyl group having a substituent.

Growing community of inventors

Yonago, Japan

Eiji Nanba